Clinical trial
Efficacy and Safety of Insulin Glulisine in Type 1 Diabetes Mellitus
NCT00290979 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00290979 |
|---|---|
| Title | Efficacy and Safety of Insulin Glulisine in Type 1 Diabetes Mellitus |
| Official title | Evaluation of Efficacy and Safety of HMR1964 (Insulin Glulisine) in Subjects With Type 1 Diabetes Mellitus; Insulin Lispro Controlled, Open, Randomized, Parallel Group, Non-inferiority Study, for 28 Weeks |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Diabetes Mellitus, Type 1 |
| Intervention type | Drug |
| Interventions | insulin glulisine |
| Enrollment | 250 |
| Start date | Dec 1, 2004 |
| First posted | Feb 13, 2006 |
| Last update posted | Aug 26, 2009 |
| Countries | Japan |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: